Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07618325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T cell memory formation.
Trial Details
NCT Number NCT07618325
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention
Conditions
(from sponsor)		 Respiratory Syncytial Virus (RSV)
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov